SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy,...
Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy,...
3 June 2025
Gilde Healthcare announces successful sale of health-it software company Performation to Enovation, part of Legrand
Exit confirms Gilde Healthcare's investment strategy of building market-leading healthcare companies that deliver better care at lower cost Under ownership of Gilde Healthcare’s private equity fund, Performation has evolved into...
13 February 2025
Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy,...
3 June 2025
Filter & search
Fund strategy:
Loading...
These were all articles
f3b728165a